Abstract
Monoclonal gammopathy of undetermined significance (MGUS) – a precursor of multiple myeloma – is associated with shorter lifespan and cardiac, renal, neurologic, and immune-related comorbidities. There is little known about modifiable risk factors for this condition. To determine if risk of MGUS is associated with dietary factors in a racially diverse population, we conducted a United States population-based case-control study from the National Health and Nutrition Examination Survey (1988-2004), which included 373 individuals with MGUS and 1,406 matched controls. Diet was characterized by one 24-hour dietary recall, with gram intake of individual foods and beverages aggregated into groups. Unconditional multivariable logistic regressions were used to model associations between intake of several food groups and MGUS, with odds ratios (OR) and 95% confidence intervals (95% CI) reported for the highest relative to the lowest quantile of intake. Daily gram intake of several food and beverage groups were significantly associated with MGUS. MGUS was inversely associated with whole-grain bread, oats, and rice (OR 0.70; 95% CI 0.48-1.00; P<0.05), fruits (excluding juice) and vegetables (OR 0.69; 95% CI 0.52-0.93; P=0.02), vegetables (OR 0.75; 95% CI 0.56-0.99; P<0.05), tomatoes (OR 0.72; 95% CI 0.51-1.00; P<0.05), and cruciferous vegetables (OR 0.44; 95% CI 0.26-0.74; P<0.01). Direct associations were observed for sugar-sweetened beverages (OR 1.34; 95% CI 1.00-1.78; P<0.05), sugar-sweetened soft drinks (OR 1.41; 95% CI 1.01-1.96; P=0.04), and artificially sweetened soft drinks (OR 1.55; 95% CI 1.04-2.33; P=0.03). Our study shows that diet is potentially a modifiable risk factor for MGUS.
Competing Interest Statement
JH serves on the advisory boards of Adaptive, Amgen, Axxess Networks, Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Oncopeptides, ONCOtracker, Sanofi, and Skyline; has given talks at Amgen, BeiGene, Beijing Medical Award Foundation, Curio Science, and Janssen Biotech; and serves on the data and safety monitoring board of Janssen Biotech. UAS reports grants from NIH/NCI Cancer Center Support Grant P30CA008748, MSK Paul Calabresi Career Development Award for Clinical Oncology K12CA184746, Paula and Rodger Riney Foundation, Allen Foundation Inc, Parker Institute for Cancer Immunotherapy at MSK, HealthTree Foundation, and International Myeloma Society as well as non-financial support from American Society of Hematology Clinical Research Training Institute, TREC Training Workshop R25CA203650 (PI: Melinda Irwin). UAS also reports research funding support from Celgene/BMS and Janssen to the institution, nonfinancial research support from Plantable, Sabinsa pharmaceuticals, and M&M labs to the institution; personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH LifeSciences, Intellisphere, Phillips Gilmore Oncology Communications, RedMedEd and i3Health outside the submitted work. SEM is deceased. JMJ, LT, KBM, AML, OL, and SZU declare no potential competing interests.
Funding Statement
This study is funded in part through the NIH/NCI Cancer Center Support Grant at Memorial Sloan Kettering P30 CA008748. U.A. Shah received research and salary support from the NCI MSK Paul Calabresi Career Development Award for Clinical Oncology K12 CA184746 and American Society of Hematology Scholar Award. She also received research funding from the Paula and Rodger Riney Foundation and HealthTree Foundation. J.M. Joseph is partially supported by the Roswell Park Alliance Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Original datasets are publicly available from the Centers for Disease Control and Prevention. https://wwwn.cdc.gov/nchs/nhanes/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes